GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Float Percentage Of Total Shares Outstanding

AMEUF (Anteris Technologies) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jan. 18, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Anteris Technologies's float shares is 0.00 Mil. Anteris Technologies's total shares outstanding is 21.14 Mil. Anteris Technologies's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Anteris Technologies's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Anteris Technologies's Institutional Ownership is 1.94%.


Anteris Technologies Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Anteris Technologies's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/21.14
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies Business Description

Traded in Other Exchanges
Address
9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. It is also engaged in research and development of ComASUR, a delivery system that allows accurate valve placement, and the manufacturing and selling of proprietary ADAPT regenerative tissue products. The company generates a majority of its revenue from the United States and the rest from Switzerland and Australia.